GSK超10亿美元“扫货”映恩生物 ADC领域下一步趋势如何?

21世纪经济报道
04 Dec 2024

12月4日,Duality Biologics(映恩生物)宣布已与葛兰素史克(GSK)就一项潜在同类最佳ADC药物(DB-1324)达成独家授权协议。根据协议条款,GSK将预先支付3000万美元预付款及其他行权前里程碑付款,以获得在全球范围内(不包括中国内地、香港地区和澳门地区)推进该ADC药物的研发与商业化进程。  此外,如果GSK行使许可权,映恩生物将收取行权费以及后续在开发、法规注册和商业化...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10